Phone : +8801712414074 || Email : support@oriopharma.com
Facebook Twitter Pinterest linkedin Telegram
  • CONTACT US
  • FAQs
Facebook Twitter Pinterest linkedin Telegram
Orio pharma Orio pharma
Select category
  • Select category
  • Bladder Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Diabetic
  • Endometrial Cancer
  • Hepatitis B Virus
  • Hepatitis C Virus
  • Leukaemia
  • ONCOLOGY PRODUCTS
  • Rectal Cancer
  • Solid Tumor
  • Taskin
    • Anti-Diabetic
    • BEST SELLER
    • Bladder Cancer
    • Breast Cancer
    • Colon & Rectal Cancer
    • Colorectal Cancer
    • Diabetic
    • Endometrial Cancer
    • Hepatitis B Virus
    • Hepatitis C Virus
    • Ibrutinib
    • Kidney Cancer
    • Leukaemia
    • Liver Cancer
    • Lung Cancer
    • Lymphoma
    • Mantle Cell Lymphoma
    • Melanoma
    • Non-Hodgkin
    • ONCOLOGY
    • ONCOLOGY PRODUCTS
      • Ovarian Cancer
      • Pancreatic Cancer
      • Peritoneal Cancer
      • Primary Biliary Cirrhosis
      • Prostate Cancer
      • Renal Cell Carcinoma
      • Rheumatoid Arthritis
      • Thrombocytopenia
      • Thyroid Cancer
      • Tumors Cancer
  • Tumor
Login / Register
0 Wishlist
0 Compare
0 items / £0.00
Menu
Orio pharma Orio pharma
0 items / £0.00
Browse Categories
  • Anti-Diabetic
  • BEST SELLER
  • Bladder Cancer
  • Breast Cancer
  • Colon & Rectal Cancer
  • Colorectal Cancer
  • Diabetic
  • Endometrial Cancer
  • Hepatitis B Virus
  • Hepatitis C Virus
  • Ibrutinib
  • Kidney Cancer
  • Leukaemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Mantle Cell Lymphoma
  • Melanoma
  • Non-Hodgkin
  • ONCOLOGY
  • ONCOLOGY PRODUCTS
  • Ovarian Cancer
  • Pancreatic Cancer
  • Peritoneal Cancer
  • Primary Biliary Cirrhosis
  • Prostate Cancer
  • Renal Cell Carcinoma
  • Rheumatoid Arthritis
  • Thrombocytopenia
  • Thyroid Cancer
  • Tumors Cancer
  • Home
  • ONCOLOGY PRODUCTS
  • UPLOAD PRESCRIPTION
CRIZOCENT
Click to enlarge
HomeShopTaskinONCOLOGY PRODUCTSOvarian Cancer CRIZOCENT 250 MG
Previous product
COVIRIN
COVIRIN 200MG
Back to products
Next product
CRIZONIX
CRIZONIX 250 MG

CRIZOCENT 250 MG

Compare
Add to wishlist
Categories: BEST SELLER, Bladder Cancer, Bladder Cancer, Breast Cancer, Breast Cancer, Colorectal Cancer, Hepatitis C Virus, Kidney Cancer, Liver Cancer, Lung Cancer, ONCOLOGY, ONCOLOGY PRODUCTS, ONCOLOGY PRODUCTS, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Prostate Cancer, Rectal Cancer, Renal Cell Carcinoma, Thyroid Cancer, Tumors Cancer Tags: Beacon Pharmaceuticals Ltd., CRIZOCENT, CRIZOCENT 250 MG, CRIZOTINIB, Incepta Pharmaceuticals Ltd, Medicine In Bangladesh Bangladesh, Oncology, Oncology Medicine
Share
Facebook Twitter Pinterest linkedin Telegram
  • Description
  • Reviews (0)
  • Shipping & Delivery
Description

Presentation

Crizocent 250: Each capsule contains Crizotinib INN 250 mg

Description

Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), ROS1 (c-ros), and Recepteur d’Origine Nantais (RON). Translocations can affect the ALK gene resulting in the expression of oncogenic fusion proteins. The formation of ALK fusion proteins results in activation and dysregulation of the gene’s expression and signaling which can contribute to increased cell proliferation and survival in tumors expressing these proteins. Crizotinib demonstrated concentration-dependent inhibition of ALK, ROS1, and c-Met phosphorylation in cell-based assays using tumor cell lines and demonstrated antitumor activity in mice bearing tumor xenografts that expressed echinoderm microtubule-associated protein-like 4 (EML4)- or nucleophosmin (NPM)-ALK fusion proteins or c-Met.

Indications

Crizotinib is a kinase inhibitor indicated for the treatment of patients with-

• Metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive

• Metastatic NSCLC whose tumors are ROS1-positive

Dosage & Administration

Recommended Dose: 250 mg orally, twice daily
• Renal Impairment: 250 mg orally, once daily in patients with severe renal impairment (creatinine clearance <30 mL/min) not requiring dialysis.

Geriatric Use
No differences in safety or efficacy were observed between older and younger patients. Clinical studies of Crizotinib in patients with ROS1-positive metastatic NSCLC did not include sufficient numbers of patients age 65 years and older to determine whether they respond differently from younger patients

Hepatic Impairment
Caution should be used in patients with hepatic impairment

Renal Impairment
No starting dose adjustment is needed for patients with mild (CLcr 60-89 mL/min) or moderate (CLcr 30-59 mL/min) renal impairment based on a population pharmacokinetic analysis.
Increased exposure to crizotinib occurred in patients with severe renal impairment (CLcr <30 mL/min) not requiring dialysis. Crizotinib should be administered at a dose of 250 mg taken orally once daily in patients with severe renal impairment not requiring dialysis.
Pediatric Dose
The safety and effectiveness of Crizotinib in pediatric patients have not been established.

Side Effects

The most common adverse reactions (≥25%) are vision disorders, nausea, diarrhea, vomiting, edema, constipation, elevated transaminases, fatigue, decreased appetite, upper respiratory infection, dizziness, and neuropathy.

Precautions

Hepatotoxicity: Patients should undergo periodic liver testing. Crizotinib should be temporarily suspended, dose reduced or permanently suspended
• Interstitial lung disease (ILD)/ Pneumonitis: Drug should be permanently discontinued in patients with ILD/ Pneumonitis
• QT interval prolongation: Electrocardiograms and electrolytes in patients who have a history of or predisposition for QTc prolongation, or who are taking medications that prolong QT should be monitored. Crizotinib should be temporarily suspended, dose reduced or permanently suspended
• Bradycardia: Crizotinib can cause bradycardia. Heart rate and blood pressure should be regularly monitored. Crizotinib should be temporarily suspended, dose reduced or permanently suspended
• Severe visual loss: Ophthalmological evaluation should be performed. Crizotinib should be discontinued in severe visual loss
• Embryo-fetal toxicity: Crizotinib can cause fetal harm. Females of reproductive potential should be advised of the potential risk to a fetus and use of effective contraception

Use in Pregnancy & Lactation

Based on its mechanism of action, Crizotinib can cause fetal harm when administered to a pregnant woman. There are no available data on the use of Crizotinib during pregnancy. Females of reproductive potential should be advised of the potential risk to a fetus and use of effective contraception.
There is no information regarding the presence of Crizotinib in human milk, the effects on the breastfed infant, or the effects on milk production. Because of the potential for adverse reactions in breastfed infants patients should not breastfeed during treatment with Crizotinib and for 45 days after the final dose.
Geriatric Use
No differences in safety or efficacy were observed between older and younger patients. Clinical studies of Crizotinib in patients with ROS1-positive metastatic NSCLC did not include sufficient numbers of patients age 65 years and older to determine whether they respond differently from younger patients

Hepatic Impairment
Caution should be used in patients with hepatic impairment

Renal Impairment
No starting dose adjustment is needed for patients with mild (CLcr 60-89 mL/min) or moderate (CLcr 30-59 mL/min) renal impairment based on a population pharmacokinetic analysis.
Increased exposure to crizotinib occurred in patients with severe renal impairment (CLcr <30 mL/min) not requiring dialysis. Crizotinib should be administered at a dose of 250 mg taken orally once daily in patients with severe renal impairment not requiring dialysis

Drug Interaction

CYP3A Inhibitors: Concurrent use of Crizotinib should be avoided with strong CYP3A inhibitors including but not limited to atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, and voriconazole
CYP3A Inducers: Concurrent use of Crizotinib should be avoided with strong CYP3A inducers including but not limited to carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, and St. John’s Wort
CYP3A Substrates: Concurrent use of Crizotinib should be avoided with CYP3A substrates with narrow therapeutic indices including but not limited to alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus

Commercial Pack

Crizocent 250: Each box contains 3 blister strips of 4 capsules
Crizocent 250: Each bottle contains 60 capsules

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “CRIZOCENT 250 MG” Cancel reply

Your email address will not be published. Required fields are marked *

Shipping & Delivery

Related products

IBRUNIB
Compare
Close

IBRUNIB 140 MG

IBRUNIB Strength 140 mg Packing 1 X 30 Capsules (Plastic Container) Storage Store below 30°C. Keep capsules in the original
Add to wishlist
Read more
Quick view
ELOPAG
Compare
Close

ELOPAG 50 MG

 Elopag Tablet Eltrombopag Olamine 50 mg Everest Pharmaceuticals Ltd. Also available as: 25 mg Indications Eltrombopag Olamine is indicated in Chronic
Add to wishlist
Read more
Quick view
CABOXEN
Compare
Close

CABOXEN 80 MG

DESCRIPTION CABOXEN CABOZANTINIB GABOXEN 20 cspsule: Eech cegsule conains Ceboa?nib (S/malate INN equivalent to 20 mg Cabozantinib. CABOXEN 80 capsule:
Add to wishlist
Read more
Quick view
LEVAT
Compare
Close

LEVAT 10 MG

 Levat Capsule Lenvatinib Mesylate 10 mg Julphar Bangladesh Ltd. Indications Lenvatinib is a kinase inhibitor that is indicated: For the treatment
Add to wishlist
Read more
Quick view
AFANIX
Compare
Close

AFANIX 40 MG

DESCRIPTION Afatinib is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC)
Add to wishlist
Read more
Quick view
LARONIB
Compare
Close

LARONIB 100 MG

DESCRIPTION Laronib Larotrectinib 25 mg & 100 mg COMPOSITION LARONIB 25 capsules: Each capsule contains Larotrectinib Sulfate INN equivalent to
Add to wishlist
Read more
Quick view
ELOPAG
Compare
Close

ELOPAG 25 MG

 Elopag Tablet Eltrombopag Olamine 25 mg Everest Pharmaceuticals Ltd. Indications Eltrombopag Olamine is indicated in Chronic Immune (Idiopathic) Thrombocytopenia, Chronic Hepatitis
Add to wishlist
Read more
Quick view
HERNIX
Compare
Close

HERNIX 40 MG

 Hernix Tablet Neratinib 40 mg Beacon Pharmaceuticals Ltd. Indications Neratinib is a kinase inhibitor indicated for the extended adjuvant treatment of
Add to wishlist
Read more
Quick view
Vitra
Magisso
Louis Poulsen
KLÖBER
Joseph Joseph
Hay
Flos
Eva Solo
Alessi

OrioPharma is one of the leading and most reputed finished pharmaceutical products suppliers in Bangladesh.

48/A-B, Baitul Khair, Level-9, Purana Paltan,Dhaka-1000
Phone: +8801712414074
Whatsapp & WeChat: +8801712414074
Recent Posts
  • ASA_apnea_side_effects
    Elopag 50 side effects
    October 19, 2021 No Comments
  • osicent-80mg-30s-500x500-500x500-1
    Osicent 80 Uses
    October 19, 2021 No Comments
ONCOLOGY
  • Bladder Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Hepatitis B Virus
  • Hepatitis C Virus
ONCOLOGY
  • Bladder Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Hepatitis B Virus
  • Hepatitis C Virus
Company
  • Terms and Conditions
  • Privacy Policies
  • UPLOAD PRESCRIPTION
  • Contact Us
www.oriopharma.com 2021 CREATED BY -SHUKHI IT
payments

Shopping cart

close
  • Menu
  • Categories
  • Anti-Diabetic
  • BEST SELLER
  • Bladder Cancer
  • Breast Cancer
  • Colon & Rectal Cancer
  • Colorectal Cancer
  • Diabetic
  • Endometrial Cancer
  • Hepatitis B Virus
  • Hepatitis C Virus
  • Ibrutinib
  • Kidney Cancer
  • Leukaemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Mantle Cell Lymphoma
  • Melanoma
  • Non-Hodgkin
  • ONCOLOGY
  • ONCOLOGY PRODUCTS
  • Ovarian Cancer
  • Pancreatic Cancer
  • Peritoneal Cancer
  • Primary Biliary Cirrhosis
  • Prostate Cancer
  • Renal Cell Carcinoma
  • Rheumatoid Arthritis
  • Thrombocytopenia
  • Thyroid Cancer
  • Tumors Cancer
  • Home
  • ONCOLOGY PRODUCTS
  • UPLOAD PRESCRIPTION
  • Wishlist
  • Compare
  • Login / Register

Sign in

close

Lost your password?
No account yet? Create an Account
Scroll To Top